Idxg stock.

The estimated Net Worth of Thomas W. Burnell is at least $437 millier dollars as of 21 May 2021. Dr Burnell owns over 10,855 units of Interpace Biosciences Inc stock worth over $12,158 and over the last 3 years he sold IDXG stock worth over $0. In addition, he makes $425,004 as Pres et CEO & Director at Interpace Biosciences Inc.© Valve Corporation. Tous droits réservés. Toutes les marques commerciales sont la propriété de leurs titulaires aux États-Unis et dans d'autres pays.Interpace Biosciences Inc (IDXG) stock is down -31.64% while the S&P 500 is up 0.35% as of 2:31 PM on Monday, Aug 17. IDXG is down -$1.83 from the previous closing price of $5.78 on volume of 968,030 shares. Over the past year the S&P 500 has risen 15.77% while IDXG is down -47.33%. IDXG lost -$8.53 per share the over the last 12 months.Pennsylvania and Connecticut Labs Both Receive Accreditation. PARSIPPANY, NJ, April 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has received the College of American Pathologists (“CAP”) accreditation for its Pittsburgh, Pennsylvania and New Haven, …1.31. Shareholder percentage totals can add to more than 100% because some holders are included in the free float. The latest Interpace Biosciences stock prices, stock quotes, news, and IDXG ...

IDXG Interpace Biosciences Inc PDI Announces Preliminary Guidance for 2004 of $1.15 to $1.25 Consolidated EPSInterpace Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. IDXG updated stock price target summary. --- - Interpace Biosciences, Inc. (NASDAQ:IDXG) major shareholder Peter Kamin bought 83,250 shares of the companys stock in a transaction that occurred on Monday, March 1st. The stock was bought at an average price of $3.12 per share, with a total value of $259,740.00.

The estimated Net Worth of Thomas W. Burnell is at least $437 Тысяча dollars as of 21 May 2021. Dr Burnell owns over 10,855 units of Interpace Biosciences Inc stock worth over $11,832 and over the last 2 years he sold IDXG stock worth over $0. In addition, he makes $425,004 as Pres и CEO & Director at Interpace Biosciences Inc.About the Interpace Biosciences, Inc. stock forecast. As of 2023 December 03, Sunday current price of IDXG stock is 1.030$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Interpace Biosciences stock price has been showing a declining tendency so we believe that similar market segments were …

Interpace Diagnostics to Present New Data in Six Posters Related to PancraGEN™ at Upcoming Annual DDW International Meeting on May 6-9, 2017 PR NewswireIDXG is important to the diagnostics industry. The company has been transformed. Seeking Alpha - Go to Homepage. Trending. My Portfolio. My Authors. Top Stocks. Latest News. Markets. Stock Ideas.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.IDXG Overview Stock Screener Earnings Calendar Sectors | IDXG U.S.: OTC Interpace Biosciences Inc. Watch list NEW Set a price target alert Closed Last Updated: Nov 1, 2023 3:48 p.m. EDT...Jun 5, 2023 · 06/05/2023 - 04:05 PM . PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) which establishes non-coverage for the Company’s widely used PancraGEN ...

NASDAQ Health Care/Life Sciences Compare to Open 0.90 Prior Close 1.00 (11/07/23) 1 Day IDXG -5.00% DJIA 0.17% Russell 2K -0.28% Health Care/Life Sciences 1.90% …

Get the latest Interpace Biosciences, Inc. (IDXG) stock news and headlines to help you in your trading and investing decisions.

PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended ...Oct 17, 2023 · IDXG Interpace Biosciences Inc Amended Statement of Beneficial Ownership (sc 13d/a) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities ... Gregory Richard - IDXG / Interpace Diagnostics Group, Inc. - Insider Trade Report ... (Stocks) Options Flow - Last 7 Days (ETF) Gamma Squeeze; Gamma Pockets; Put/Call Ratio - Top Bullish; Put Call Ratio - Top Bearish; SEC FILINGS SEC Forms Latest S1 (IPO) Filings Latest 13D/G Filings Latest 13F Filings. SCREENEREstablishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.EPS is the net income, or profit, a company generates during a period for each share of common stock it has outstanding. Zacks News for IDXG TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue ...EPS forecast (this quarter) $0.11. Annual revenue (last year) $31.8M. Annual profit (last year) -$22.0M. Net profit margin. -18.42%.

IDXG Stock Return DVA Stock Return ... We favor stocks that offer meaningfully greater expected return in the next 3 years; These returns are calculated based on our revenue forecast and Price to Sales Ratio (P/S) scenarios considered; Similar Price To Sales Ratio (P/S) scenarios are considered for both stocks and each scenario is weighted ...Interpace Diagnostics Stock Earnings. The value each IDXG share was expected to gain vs. the value that each IDXG share actually gained. Interpace Diagnostics ( IDXG) reported Q3 2022 earnings per share (EPS) of -$3.35, missing estimates of -$0.25 by 1,239.76%. In the same quarter last year, Interpace Diagnostics 's earnings per share (EPS) was ...PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") IDXG today announced financial results for the third quarter ended September 30, 2023 ...James has made over 1 trades of the Interpace Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently James exercised 5,000 units of IDXG stock worth $5,750 on 29 July 2020. The largest trade James's ever made was exercising 5,000 units of Interpace Biosciences Inc stock on 29 July 2020 worth over $5,750.Interpace Biosciences on Wednesday said it had closed the sale of its pharma services business to Flagship Biosciences.IDXG CEO Thomas Burnell said with the completion of the deal, the company's ...6201 15th Avenue. Brooklyn, NY 11219. T: 718-921-8300. [email protected]. www.astfinancial.com. Interpace Biosciences® is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer. Interpace Biosciences is a fully integrated commercial and ...

Third quarter Net Revenue was. Find the latest Interpace Diagnostics Group, Inc. (IDXG) stock quote, history, news and other vital information to help you with your stock trading …

On average, Interpace Biosciences Inc executives and independent directors trade stock every 99 days with the average trade being worth of $29,732. The most recent stock trade was executed by Thomas W. Burnell on 21 May 2021, trading 10,855 units of IDXG stock currently worth $94,221.James Early IDXG stock SEC Form 4 insiders trading. James has made over 1 trades of the Interpace Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently James exercised 5,000 units of IDXG stock worth $4,750 on 29 July 2020.5,000 units of IDXG stock worth $4,750 on 29 July 2020.Log In – – % – – % – – % – – % – – % – – % Data & APIsDiscover the top 3 undervalued Managed Health care stocks for Monday, November 20 based on AAII’s Stock Grades. Eunice Kim. Stock Grade Focus Is Interpace Biosciences Inc (IDXG) Stock a Good Investment?Company to Host Fellowship and Key Opinion Leader Programs. PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of …IDXG: Interpace Biosciences - Companarative Chart. Get the latest Comparative Chart for Interpace Biosciences from Zacks Investment ResearchIDXG Earnings Date and Information. Interpace Biosciences last issued its earnings results on November 8th, 2023. The business services provider reported ($0.12) EPS for the quarter. The business had revenue of $9.08 million for the quarter.Dr D IDXG stock SEC Form 4 insiders trading. Dr has made over 1 trades of the Interpace Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,855 units of IDXG stock worth $94,221 on 21 May 2021.10,855 units of IDXG stock worth $94,221 on 21 May 2021.

Suite 310. 2001 Route 46. Parsippany, New Jersey 07054. Phone 1 855 776-6419. Industry Medical Equipment/Supplies. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $31.84M.

WalletInvestor is an investment research platform designed to help users find profitable trading opportunities. This platform covers more than 100,000 assets, including stocks, ETFs, forex, cryptocurrencies, and commodities. WalletInvestor offers 7-day, 3-month, 1-year, and 5-year price targets for each asset using a machine learning algorithm.

IDXG is the ticker symbol for Interpace Biosciences, Inc., a company that provides molecular diagnostic tests for cancer and other diseases. The stock price, news, quote and history of IDXG are shown on Yahoo Finance, as well as its performance outlook, earnings, dividends and research reports. MiMedx Group (MDXG, $7.57) RSI Indicator left the overbought zone on November 22, 2023. Track Mimedx Group Inc (MDXG) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors. LKNCY Stock. Located in the Cayman Islands, Luckin Coffee Inc. (OTC: LKNCY, STU: LC0A) is a holding company that provides retail services for freshly brewed coffee and other beverages. It conducts business in the People's Republic of China.IDXG reverse stock split: 1 for 10: Dec 29, 2016: DS: Symbol Change: NCT ticker symbol changed to DS: Dec 29, 2016: BKYI: Stock Split: BKYI reverse stock split: 1 for 12:PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February 16, 2020 it had received notification from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock market LLC (“Nasdaq”) that …٦ جمادى الآخرة ١٤٣٩ هـ ... IDXG signed a new national contract with Aetna for its ThyGenX ... to a particular stock represents solely the analyst's view of how that stock ...Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies. RNAscope ® in situ hybridization (ISH) is a new Interpace offering that …David Kerr Senior VP Business Development at Interpace Diagnostics Group, is currently unranked, see this insider's latest transactions.Track Interpace Biosciences Inc (IDXG) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

You can watch IDXG and buy or sell other stocks, options, and ETFs commission-free! You can watch IDXG and buy and sell other stock and options commission-free on Robinhood. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Interpace Biosciences against related stocks people have also ... 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Interpace Biosciences Inc. 1.05. Delayed Data. As of Nov 21. -0.09 / -7.89%. Today’s Change. 0.51. Today ||| 52-Week Range. 3.54.Instagram:https://instagram. kandi dallasstock market ytd returnpetrobras sharesroots reit review Nov 21, 2023 · Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $8.3M Mar. 27: MT Interpace Biosciences, Inc. Auditor Raises 'Going Concern' Doubt Mar. 26: CI Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q3 Revenue $8.19M Nov. 14: MT PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million. Under the terms of the Rights Offering, the Company is distributing non-transferable subscription … real estate investing with little moneye option The estimated Net Worth of Thomas W. Burnell is at least $435 Thousand dollars as of 21 May 2021. Dr Burnell owns over 10,855 units of Interpace Biosciences Inc stock worth over $10,204 and over the last 3 years he sold IDXG stock worth over $0. In addition, he makes $425,004 as Pres and CEO & Director at Interpace Biosciences Inc.Nov 28, 2023 · EPS is the net income, or profit, a company generates during a period for each share of common stock it has outstanding. Zacks News for IDXG TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue ... buy carnival stock Lihat berita, harga saham, data fundamental, teknikal analisis dan laporan keuangan saham IDXG30 (IDX Growth 30) Investasi, Nabung, Beli atau Jual sahamnya secara online dengan mudah.IDXG Earnings Date and Information. Interpace Biosciences last issued its earnings results on November 8th, 2023. The business services provider reported ($0.12) EPS for the quarter. The business had revenue of $9.08 million for the quarter.